Recent Updates
Recently added Catalysts
AMIX Positive Sentiment Score: 70/100

Autonomix Medical, Inc. (NASDAQ: AMIX) to Participate in the Virtual Investor Closing Bell Series

Key Takeaway: Autonomix Medical, Inc. (NASDAQ: AMIX) will participate in the Virtual Investor Closing Bell Series on May 16, 2024. CEO Lori Bisson will present a corporate overview and discuss business outlook, with a Q&A session for investors. The company's innovative technology aims to transform the diagnosis and treatment of diseases involving the nervous system, with a focus on severe conditions like pancreatic cancer pain.

Market Sentiment Analysis

POSITIVE FACTORS

  • Participation in a notable investor event, enhancing visibility.
  • CEO will present a corporate overview and business outlook.
  • Innovative technology with the potential to revolutionize diagnosis and treatment.

Full Press Release Details

Live webcast on Thursday, May 16th at 4:00 PM ET
THE WOODLANDS, TX, May 14, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced that it will participate in the Virtual Investor Closing Bell Series on Thursday, May 16, 2024 at 4:00 PM ET.
As part of the event, Lori Bisson, Chief Executive Officer of Autonomix, will provide a corporate overview and business outlook. In addition to the moderated discussion, investors and interested parties will have the opportunity to submit questions live during the event. The Company will answer as many questions as possible in the time allowed.
A live video webcast will be available on the Events page under the Investors section of the Company’s website (autonomix.com). A webcast replay will be available two hours following the live event and will be accessible for 90 days.
About Autonomix Medical, Inc.
Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company’s first-in-class technology platform includes a catheter-based microchip sensing array that has the ability to detect and differentiate neural signals with approximately 3,000 times greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body.
We are initially developing our technology for pancreatic cancer pain, a condition that can cause debilitating pain and needs an effective solution. However, our technology constitutes a platform with the potential to address dozens of indications, including in cardiology, renal denervation and chronic pain management across a wide disease spectrum.
For more information, visit autonomix.com and connect with the Company on X, LinkedIn, Instagram and Facebook.
Investor and Media Contact

Tags

Virtual Investor Closing Bell
medical device company
innovative technologies

Frequently Asked Questions

When will the Autonomix webcast take place?

The Autonomix webcast is scheduled for May 16, 2024, at 4:00 PM ET.

Who will present at the Virtual Investor Closing Bell?

Lori Bisson, the CEO of Autonomix, will provide the corporate overview.

How can I access the live webcast?

You can access the live webcast on the Investors section of autonomix.com.

What technology is Autonomix developing?

Autonomix is developing a catheter-based microchip sensing array for neural signal detection.

What initial condition does Autonomix focus on?

Autonomix is initially targeting pancreatic cancer pain with its technology.

Last updated: May 14, 2024